MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qad.0000000000003405

Медицинская библиотека · AIDS (London, England) · 2022

Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV.

Chambers Catharine, Samji Hasina, Cooper Curtis L, Costiniuk Cecilia T, Janjua Naveed Z, Kroch Abigail E, Arbess Gordon, Benoit Anita C, Buchan Sarah A, Chung Hannah, Kendall Claire E, Kwong Jeffrey C, Langlois Marc-André, Lee Samantha M, Mbuagbaw Lawrence, McCullagh John, Moineddin Rahim, Nambiar Devan, Walmsley Sharon, Anis Aslam H, Burchell Ann N, for the COVAXHIV Study Team

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

People with HIV were underrepresented in coronavirus disease 2019 (COVID-19) vaccine clinical trials. We estimated vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for the BNT162b2, mRNA-1273, and ChAdOx1 vaccines among a population-based cohort of people with HIV in Ontario, Canada.

DESIGN

Test-negative design.

METHODS

We identified people with HIV aged ≥19 years who were tested for SARS-CoV-2 by RT-PCR between December 14, 2020 (first availability of COVID-19 vaccines) and November 21, 2021 (pre-Omicron circulation). Outcomes included any infection, symptomatic infection, and COVID-19-related hospitalization/death. We compared the odds of vaccination between test-positive cases and test-negative controls using multivariable logistic regression with adjustment for age, sex, region, calendar time, SARS-CoV-2 test histories, influenza vaccination, comorbidities, and neighborhood-level socio-economic status. VE was derived as (1 - adjusted odds ratio) × 100%.

RESULTS

Among 21 023 adults living with HIV, there were 801 (8.3%) test-positive cases and 8,879 (91.7%) test-negative controls. 20.1% cases and 47.8% of controls received ≥1 COVID-19 vaccine dose; among two-dose recipients, 93.4% received ≥1 mRNA dose. Two-dose VE ≥7 days before specimen collection was 82% (95% confidence interval [CI] = 74-87%) against any infection, 94% (95% CI = 82-98%) against symptomatic infection, and 97% (95% CI = 85-100%) against hospitalization/death. Against any infection, VE declined from 86% (95% CI = 77-92%) within 7-59 days after the second dose to 66% (95% CI = -15-90%) after ≥180 days; we did not observe evidence of waning protection for other outcomes.

CONCLUSION

Two doses of COVID-19 vaccine offered substantial protection against symptomatic illness and hospitalization/death in people with HIV prior to the emergence of the Omicron variant. Our findings do not support a broad conclusion that COVID-19 VE is lower among people with HIV in populations that, for the most part, are attending HIV care, taking antiretroviral medication, and are virally suppressed.

Для цитирования: Chambers Catharine, Samji Hasina, Cooper Curtis L, Costiniuk Cecilia T, Janjua Naveed Z, Kroch Abigail E, Arbess Gordon, Benoit Anita C, Buchan Sarah A, Chung Hannah, Kendall Claire E, Kwong Jeffrey C, Langlois Marc-André, Lee Samantha M, Mbuagbaw Lawrence, McCullagh John, Moineddin Rahim, Nambiar Devan, Walmsley Sharon, Anis Aslam H, Burchell Ann N, for the COVAXHIV Study Team. Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV.. AIDS (London, England). 2022. DOI: 10.1097/qad.0000000000003405.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.